title: Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder.
abstract: BACKGROUND
  Secretin is a peptide hormone that stimulates pancreatic secretion. After recent publicity about a child with autism whose condition markedly improved after a single dose of secretin, thousands of children with autistic disorders may have received secretin injections.
  
  
  METHODS
  We conducted a double-blind, placebo-controlled trial of a single intravenous dose of synthetic human secretin in 60 children (age, 3 to 14 years) with autism or pervasive developmental disorder. The children were randomly assigned to treatment with an intravenous infusion of synthetic human secretin (0.4 microg per kilogram of body weight) or saline placebo. We used standardized behavioral measures of the primary and secondary features of autism, including the Autism Behavior Checklist, to assess the degree of impairment at base line and over the course of a four-week period after treatment.
  
  
  RESULTS
  Of the 60 children, 4 could not be evaluated - 2 received secretin outside the study, and 2 did not return for follow-up. Thus, 56 children (28 in each group) completed the study. As compared with placebo, secretin treatment was not associated with significant improvements in any of the outcome measures. Among the children in the secretin group, the mean total score on the Autism Behavior Checklist at base line was 59.0 (range of possible values, 0 to 158, with a larger value corresponding to greater impairment), and among those in the placebo group it was 63.2. The mean decreases in scores over the four-week period were 8.9 in the secretin group and 17.8 in the placebo group (mean difference, -8.9; 95 percent confidence interval, -19.4 to 1.6; P=0.11). None of the children had treatment-limiting adverse effects. After they were told the results, 69 percent of the parents of the children in this study said they remained interested in secretin as a treatment for their children.
  
  
  CONCLUSIONS
  A single dose of synthetic human secretin is not an effective treatment for autism or pervasive developmental disorder.
authors.affiliation: Olson Huff Center for Child Development, Thoms Rehabilitation Hospital, Asheville, NC 28803, USA. adsandler@pol.net
authors.forename: A D
authors.initials: AD
authors.lastname: Sandler
authors.forename: K A
authors.initials: KA
authors.lastname: Sutton
authors.forename: J
authors.initials: J
authors.lastname: DeWeese
authors.forename: M A
authors.initials: MA
authors.lastname: Girardi
authors.forename: V
authors.initials: V
authors.lastname: Sheppard
authors.forename: J W
authors.initials: JW
authors.lastname: Bodfish
mesh_terms: D000293:Adolescent; D001321:Autistic Disorder / Q000188:drug therapy*; D002648:Child; D002659:Child Development Disorders, Pervasive / Q000188:drug therapy; D002675:Child, Preschool; D004311:Double-Blind Method; D006801:Humans; D012633:Secretin / Q000008:administration & dosage*; D017211:Treatment Failure
chemical_list: D012633:Secretin